Compare · BSX vs NVAC
BSX vs NVAC
Side-by-side comparison of Boston Scientific Corporation (BSX) and NorthView Acquisition Corporation (NVAC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and NVAC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $92.25B, about 391.5x NVAC ($235.6M).
- Over the past year, BSX is down 39.2% and NVAC is up 0.0% - NVAC leads by 39.2 points.
- BSX has hit the wire 3 times in the past 4 weeks while NVAC has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 0 for NVAC).
- Company
- Boston Scientific Corporation
- NorthView Acquisition Corporation
- Price
- $62.06-5.52%
- $11.37+0.98%
- Market cap
- $92.25B
- $235.6M
- 1M return
- -11.05%
- +0.00%
- 1Y return
- -39.23%
- +0.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
NorthView Acquisition Corporation
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
Latest BSX
- Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Latest NVAC
- SEC Form 3 filed by new insider Asarpota Rajesh
- New insider Hwang Ben Chung-Bin claimed ownership of 844,228 shares (SEC Form 3)
- NorthView Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Change in Shell Company Status, Other Events
- SEC Form DEF 14C filed by NorthView Acquisition Corporation
- SEC Form CERT filed by NorthView Acquisition Corporation
- SEC Form 8-A12B filed by NorthView Acquisition Corporation
- SEC Form 425 filed by NorthView Acquisition Corporation
- NorthView Acquisition Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 25-NSE filed by NorthView Acquisition Corporation
- SEC Form 424B3 filed by NorthView Acquisition Corporation